SuperworthArcutis Biotherapeutics profit margin ARQT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2024.
- Net margin, 12 months
- 6.1%
- Operating margin, 12 months
- 7.4%
- Net margin on a year earlier
- +41.5 pts
- Peer median
- 17.2%
Over the twelve months to Jun 30, 2026, Arcutis Biotherapeutics kept 6.1% of its revenue as net profit, with an operating margin of 7.4% and a gross margin of 91.1%.
The median for 10 large drugmakers of a similar size is 17.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −4.3% | −3.3% | 90.2% |
| FY2024 | −71.3% | −65.3% | 90.3% |
| FY2023 | n/a | n/a | 91.6% |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
| FY2020 | n/a | n/a | n/a |
| FY2019 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 6.1% | +41.5 pts | 7.4% | |
| Q1 FY26 | −0.6% | +60.4 pts | 0.8% | |
| Q4 FY25 | −4.3% | +67.0 pts | −3.3% | |
| Q3 FY25 | −13.9% | n/a | −12.0% | |
| Q2 FY25 | −35.4% | n/a | −32.6% | |
| Q1 FY25 | −61.0% | n/a | −57.0% | |
| Q4 FY24 | −71.3% | n/a | −65.3% | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Arcutis Biotherapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| ARQTArcutis Biotherapeutics | 6.1% |
| LQDALiquidia | 30.7% |
| INDVIndivior Pharmaceuticals | 26.7% |
| OGNOrganon | 3.4% |
| NRIXNurix Therapeutics | 42.0% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| LGNDLigand Pharmaceuticals | 67.9% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| PBHPrestige Consumer Healthcare | 15.6% |
| HRMYHarmony Biosciences | 18.9% |
| ALKSAlkermes plc. | 4.0% |
| Peer median | 17.2% |
Where Arcutis Biotherapeutics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Arcutis Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.